Winter 2025

Future Talent Program – Global Supplier Management Group Research & Development Sourcing and Procur…

Global Support Functions Division, Research & Development Sourcing & Procurement

Posted on 10/31/2025

Deadline 11/3/25
Merck

Merck

10,001+ employees

Pharmaceutical company developing medicines and vaccines

Compensation Overview

$19.04 - $50.72/hr

No H1B Sponsorship

North Wales, PA, USA + 1 more

More locations: Linden, NJ, USA

Hybrid

Category
Operations & Logistics (3)
, ,
Requirements
  • Currently in sophomore or junior level curriculum, pursuing a Bachelor’s degree in business (such as Finance or Management), Supply Chain Management, Manufacturing, Market Research, Communications or a Science-related discipline (Engineering, Statistics, Biology, Chemistry, Biochemistry or Bioengineering). Or currently enrolled in an MBA program or other graduate program.
  • Superior interpersonal skills with the demonstrated ability to work successfully on cross functional teams
  • Possess excellent verbal and written communication skills including ability to make clear and concise presentations, sensitivity to cultural differences in communication, experience with SharePoint and Enterprise Social Media (specifically Yammer), and familiarity with principles of business communication, marketing and/or journalism.
  • Strong data collection, analysis and reporting skills
  • Excellent project management skills
  • Ability to work independently with a high degree of flexibility and adaptability to deal with ambiguous and dynamic situations
  • Quick learner and motivated to cultivate technical, business and commercial skills by applying their knowledge within our company’s environment
  • Proficient in Microsoft office suite (Excel, PowerPoint, Word)
  • Demonstrated excellent academic achievement
  • Focus on process improvements and simplification
  • Prior pharmaceutical industry experience or any fortune 500 company experience
  • Experience with using SharePoint or other similar collaboration websites
  • Experience with TIBCO Spotfire or other data analytic/visualization tools
  • Experience with using Excel to manage large data sets
  • Knowledge of data collection methods (polls, focus groups, surveys)
  • GPA 3.0
Responsibilities
  • Support strategic and operating objectives for the procurement function including product sourcing, supply risk management, supplier performance improvement, cost reduction, supplier diversity development, working capital improvement, and supplier relationship management
  • Work with cross functional teams including Legal, Finance, Procure-to-Pay, internal stakeholders, and external suppliers
  • Conduct detailed market analyses looking at facts and data, with the objective of providing deep and meaningful insights
  • Implement procurement efforts and execute tactical procurement processes. Serve as a resource regarding processes, procedures and systems for procurement function.
  • Support selection of suppliers to ensure appropriate savings and service levels. Ensure that all legal contract requirements are met. Manage relationships with external contacts to ensure optimal team performance and to take appropriate actions by implementing contract negotiation, communication with suppliers and/or or modifying procedure to ensure customer satisfaction.
  • Enforce compliance with all Global Procurement policies and procedures by using a data driven business case approach.
  • Supplier and Supply Market Analysis – To conduct rigorous market intelligence and detailed supplier and supply market analyses, to provide deep and meaningful insight to Sourcing teams.
  • Cost Modeling / Cost reduction – To construct detailed cost models/purchase price analysis of goods and services that are supplied to our company. At times, this will require supplier visits to create a complete understanding of the cost structure of suppliers and develop cost reduction opportunities.
  • Supplier Performance Management – supplier performance monitoring, root cause investigation, issue management, risk assessment and mitigation
  • Strategic Analysis – To conduct up to six types of project analysis which transforms the information gathered from 1) and 2) above into insightful, well-structured breakthrough options and opportunities. Examples include Portfolio Analysis, Supplier Referencing, and Day One Sourcing.
  • Financial Analysis & Reporting – To prepare analysis and reporting of category spend, savings, compliance, and other metrics data on a monthly basis. To support the annual budget / profit planning process for the category at the global level. To maintain financial reporting and management systems (including SAP) with up-to-date data on an ongoing basis.
  • Negotiation Planning – To create detailed pre-negotiation plans, to lead and participate any prolonged negotiation sessions with suppliers and to conduct post negotiation debriefs and follow through plans.
  • Sourcing – To create and execute RFIs, RFPs, and e-Auctions, together with subsequent structured information analysis wherever possible using electronic procurement processes.
  • Risk Assessment and Mitigation – To conduct effective risk assessment (including Financial Solvency Analysis, compliance with FCPA, Business Partner Code of Conduct, etc.) and establish appropriate risk mitigation plans within the supply-base pursuant to our Manufacturing Division's risk management framework.
  • Category Team Membership – To be an active member of one or more category teams using the techniques and content created in above as input in the creation of breakthrough strategies delivering cost reduction targets.
  • Sharing of Learnings – The incumbent will be expected to generate work of world-class quality and to share and transfer this to colleagues throughout GSMG
  • Corporate Communications – To identify communications opportunities, provide guidance on communications best practices, and identify process improvements. Draft and edit articles, blogs, newsletters, and slides. Be a proactive member of the Change Agent Network.
Desired Qualifications
  • Prior pharmaceutical industry experience or any fortune 500 company experience
  • Experience with using SharePoint or other similar collaboration websites
  • Experience with TIBCO Spotfire or other data analytic/visualization tools
  • Experience with using Excel to manage large data sets
  • Knowledge of data collection methods (polls, focus groups, surveys)
  • GPA 3.0

Merck is a global healthcare company that develops medicines, vaccines, and animal health products. It advances long-term health by conducting research and development to create new treatments for diseases such as cardiovascular disease, diabetes, and cancer, then brings these medicines to patients, healthcare professionals, and institutions worldwide. The company’s products work by undergoing scientific discovery, clinical testing, and regulatory approval before being manufactured and sold or distributed through patient assistance programs. What sets Merck apart is its large, diversified portfolio across human medicines, vaccines, and animal health, along with a strong emphasis on R&D, global reach, and support services like Merck Connect and Merck Manuals that provide professional resources. Merck’s goal is to tackle major health threats by applying science to discover and deliver therapies that improve patient outcomes and public health across the globe.

Company Size

10,001+

Company Stage

IPO

Headquarters

Kenilworth, Illinois

Founded

1891

Simplify Jobs

Simplify's Take

What believers are saying

  • Multiple 2026 approvals and collaborations expand the pipeline beyond Keytruda.
  • China biotech partnerships create repeatable access to early oncology and autoimmune assets.
  • Cost cuts targeting $3 billion by 2027 can fund new launches.

What critics are saying

  • Keytruda loses patent protection in 2028, pressuring Merck's largest cash generator.
  • Gardasil faces 2028 patent loss, compounding post-Keytruda revenue decline.
  • Animal Health securities litigation could force disclosure scrutiny, settlements, and valuation damage.

What makes Merck unique

  • Merck combines blockbuster oncology, vaccines, infectious diseases, and animal health businesses.
  • Its Keytruda franchise anchors R&D, partnerships, and late-stage combination strategies.
  • Merck Life Science adds biologics testing and manufacturing-adjacent services beyond pharmaceuticals.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Merck who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Hybrid Work Options

Growth & Insights and Company News

Headcount

6 month growth

9%

1 year growth

9%

2 year growth

9%
Merck
May 15th, 2026
Merck and City Cancer Challenge expand global partnership to strengthen women's cancer care.

Merck and City Cancer Challenge expand global partnership to strengthen women's cancer care. This initiative aims to reach more than 300,000 women living with cancer around the world by 2030 May 15, 2026 Millions of women around the world are diagnosed with cancer every year. Breast, cervical, ovarian and endometrial cancers accounted for nearly one in five new cancer cases and 1.3 million deaths globally in 2022. Research suggests that some of the deaths from these cancers may be avoided through a combination of effective public health policies, earlier detection and timely medical care. At Merck, we recognize the importance of working with organizations committed to closing gaps in care for people who need it most. That's why we're expanding our partnership with City Cancer Challenge (C/Can) with a five-year, $10 million investment to improve cancer care for women in 15 cities around the world through community-led collaboration. What is City Cancer Challenge? C/Can is an international non-profit organization that brings together public and private partners at the city level to design, plan and implement practical solutions to help address gaps in cancer care. The organization leverages the unique value of cities as enablers in a health system's response to cancer. C/Can works with municipal leaders, health authorities, clinicians and patient groups in cities across low- and middle-income countries (LMICs), reaching over 764,000 patients with opportunities for improved quality of care. Supporting the thriving Cities, Healthy Women initiative. Merck has been a partner of C/Can since the organization's founding in 2019. Building on this work, we're investing in its new "Thriving Cities, Healthy Women" initiative to help close gaps in access to cancer screening and care for women in LMICs across Africa, Latin America, Southeast Asia and Eastern Europe. "Too many women are diagnosed too late, receive care too late or never receive care at all. That's not inevitable - it's fixable. Prioritizing women and health does not only benefit women and their families, it can also be a powerful lever for stronger health systems, economic resilience and social progress." * Isabel Mestres CEO, City Cancer Challenge By 2030, the partnership aims to: Reach more than 300,000 women with cancer through improved access to care Train more than 2,000 health professionals through capacity building and mentorship Benefit more than 11 million women through influencing policy, replication and scale-up of patient initiatives "People should be able to access timely cancer care - no matter where they live. By partnering with City Cancer Challenge, we're working city by city to strengthen local systems so more women can be diagnosed earlier and get the care they need close to home." * Kalahn Taylor-Clark, Ph.D., MPH Vice president and head of social impact and sustainability, Merck How we're closing the cancer care gap. Women often navigate cancer with unique responsibilities and pressures. Socioeconomic barriers, geography, caregiving demands and other factors can stand in the way of early detection and timely diagnosis. In many settings, women experience delayed referrals, unclear diagnostic pathways and long waits to access care - all of which may lead to worse outcomes. "By investing in the health of women, we invest in stronger families, resilient communities and more productive societies." * Jenelle Krishnamoorthy, Ph.D. Senior vice president and head of global policy and public affairs, Merck Through our partnership with C/Can, participating cities will work toward measurable, sustainable improvements in women's cancer care to: * Expand access to screening, as early detection may impact outcomes * Reduce the time from suspicion of cancer to confirmed diagnosis or rule-out * Increase the number of women initiating cancer care plans soon after diagnosis Discover more stories

Pharma Focus Asia
May 12th, 2026
Erasca Enters into Collaboration with Merck to Evaluate ERAS-0015 with KEYTRUDA in RAS-Mutant Solid Tumours.

Erasca Enters into Collaboration with Merck to Evaluate ERAS-0015 with KEYTRUDA in RAS-Mutant Solid Tumours. Tuesday, May 12, 2026 Erasca has entered into a clinical trial collaboration and supply agreement with Merck to evaluate ERAS-0015 in combination with KEYTRUDA for patients with RAS-mutant solid tumours. The agreement will support the AURORAS-1 clinical proof-of-concept study, which is assessing the investigational pan-RAS molecular glue ERAS-0015 together with pembrolizumab, Merck's anti-PD-1 therapy. Erasca is sponsoring the study, while Merck will provide pembrolizumab at no cost. The companies are exploring the potential of the combination therapy to improve treatment outcomes in cancers driven by RAS mutations. RAS mutations are known to activate the RAS/MAPK pathway and contribute to an immunosuppressive tumour environment. Preclinical findings suggest that ERAS-0015 may help enhance the effects of PD-1 blockade by reducing immunosuppression and supporting stronger and longer-lasting tumour responses. Globally, around 2.7 million patients are diagnosed each year with RAS-mutant tumours. Limited treatment options targeting multiple RAS mutations and the development of resistance mechanisms remain major challenges in treating these cancers. ERAS-0015 is an investigational oral therapy designed to inhibit RAS signalling across a broad range of mutations. The therapy is currently being evaluated in the Phase 1 AURORAS-1 trial in patients with RAS-mutant solid tumours. Early dose-escalation results from the study showed favourable safety and tolerability, linear pharmacokinetics, and confirmed as well as unconfirmed partial responses in patients across different tumour types and RAS mutations. Responses were observed at doses as low as 8 mg once daily. The therapy is also designed to address resistance associated with mutant-selective inhibitors through inhibition of RAS wildtype variants. In addition, ERAS-0015 demonstrated favourable absorption, distribution, metabolism, excretion, and pharmacokinetic properties in preclinical animal studies.

BJMO
May 8th, 2026
Hybrid therapy breaks through: drugs and apps used together against rare tumors.

Hybrid therapy breaks through: drugs and apps used together against rare tumors. Pharmaceuticals Remepy and Merck explore hybrid treatment approach for rare tumors, combining drugs with AI-driven digital protocols via an app to enhance effectiveness. This innovation specifically targets cancers with unmet medical needs, where behavioral support, physiotherapy, and symptom monitoring can reinforce pharmacological effects. AI-driven app The Remepy app is a personalized digital therapeutic platform delivering evidence-based interventions via a mobile application, designed to stimulate neuroplasticity, balance the immune system, and promote behavioral change. It combines multisensory stimulation (visual, auditory, and tactile) with protocols such as cognitive behavioral therapy, mindfulness, psychoeducation, sensory modulation, and physiotherapy exercises. The app simultaneously activates multiple mechanisms: it reduces systemic inflammation through stress reduction, enhances brain plasticity via enriched multisensory environments, triggers the reward system to improve therapy adherence, and improves motor control with exercises for speech, balance, and fine motor skills. For emotional and cognitive support, it provides attention training, emotion regulation, and sleep interventions - all AI-driven and personalized in real-time through patient data and smart notifications. RMPY-008 study The Remepy-conducted RMPY-008 study, a randomized controlled trial in 103 adults with subjective cognitive decline, tested the app over three weeks. The design included randomization to intervention or control, with pre- and post-measurements of inflammatory biomarkers, psychological scales, and fMRI for brain connectivity. Results showed significant reductions in pro-inflammatory cytokines (TNF-α, IL-17, IL-23, IL-12, IFN-γ, MCP-1), improved mood and resilience, and enhanced fronto-limbic connectivity, with 94% therapy adherence. Hybrid therapy collaboration The collaboration focuses on Merck's rare tumor portfolio, where hybrid therapies could reduce toxicity and improve outcomes through personalized remote care. Examples include guided physiotherapy, pain management, and medication tracking - ideal for heterogeneous diseases with high care needs. This approach leverages recent FDA frameworks for combined drug-software products, with potential for label expansions. References * Remepy press release * Catalogna, M., Saporta, N., Nathansohn-Levi, B. et al. Mobile application leads to psychological improvement and correlated neuroimmune function change in subjective cognitive decline. npj Digit. Med. 8, 359 (2025). https://doi.org/10.1038/s41746-025-01765-1

Castlefield
Apr 27th, 2026
Engagement update with Merck & co on animal testing and packaging.

Engagement update with Merck & co on animal testing and packaging. By Ffion Spencer * Share * April 27/04/2026, 12:00 AM As part of its ongoing efforts to improve performance across key environmental, social, transparency and governance (E.S.T.) metrics, Castlefield Partners Limited recently engaged with US pharmaceutical company Merck & co., held in the castlefield thoughtful World Equity Fund, to discuss its approach to animal testing, the use of animal-derived ingredients, and packaging practices. At a recent External Advisory Committee meeting, the committee highlighted increasing numbers of animals being used in animal testing across the pharmaceutical sector. Around the same time, Castlefield Partners Limited also received a client query relating to the use of animal derived ingredients in pharmaceutical products. This engagement therefore focused on three material topics for the pharmaceutical industry: animal testing, the use of animal derived ingredients in products, and plastic use. In its initial response, Merck explained that it makes extensive use of non animal research methods, including in vitro techniques, computer modelling and advanced imaging, prior to or instead of animal studies. The company shared that approximately 96% of its research animals are rodents and confirmed that it maintains detailed records on animal use across species, purpose and site, including research carried out by third party organisations on Merck's behalf. As Merck has confirmed that it maintains this data internally, Castlefield Partners Limited has encouraged greater transparency through public disclosure. Castlefield Partners Limited also encouraged the company to consider setting reduction targets on this topic. While this response suggests a baseline level of governance and oversight, Castlefield Partners Limited believe there is scope for further progress. Castlefield Partners Limited has followed up and are awaiting further written responses.Castlefield Partners Limited note that some peers, including French pharmaceutical company Sanofi, which is also held in the World Equity Fund, publish the total number of animals used for scientific research on an annual basis. As Merck has confirmed that it maintains this data internally, Castlefield Partners Limited has encouraged greater transparency through public disclosure. Castlefield Partners Limited also encouraged the company to consider setting reduction targets on this topic. On animal derived ingredients, Merck highlighted the use of specialised tools to identify potential non animal alternatives, indicating consideration of reduction and substitution where scientifically feasible. On plastics, the company shared that it has developed a long term roadmap aimed at reducing the environmental impact of its packaging, suggesting an acknowledgement of plastics as a material environmental issue within its operations. Overall, while Merck provided high level information across all three topics, the most detailed discussion related to animal testing, reflecting its materiality to the sector. Outcome: Its engagement confirmed that Merck has a level of baseline governance on these topics. However, further engagement with the company is required, particularly in relation to transparency and disclosure on the number of animals used in scientific testing. Information is accurate as at 20.04.2026. Opinions constitute the fund manager's judgement as of this date and are subject to change without warning. The officers, employees and agents of CIP may have positions in any securities mentioned herein. This material may not be distributed, published or reproduced in whole or in part. With investment, capital is at risk.

Yahoo Finance
Apr 14th, 2026
Merck keeps Keytruda cancer drug prices high as single dose reaches $163K

Merck's cancer drug Keytruda has become a pricing flashpoint in US healthcare, with a single 400mg dose billed at $162,567 at a California clinic, despite Merck's list price of $24,000. The drug generated $31.7 billion in worldwide sales in 2025, representing nearly half of Merck's revenue. A joint investigation by the International Consortium of Investigative Journalists and USA TODAY found Merck employs multiple tactics to maintain high prices, including building patent walls against generic competition, lobbying against Medicare price negotiations, and maintaining higher dosing despite studies suggesting weight-based dosing would be effective and cheaper. Whilst Merck CEO Robert Davis pledged support for President Trump's drug pricing initiatives in December, he made no commitments regarding Keytruda. Merck attributes US price inflation to pharmacy benefit managers and insurers who add fees and rebates.

INACTIVE